TrialAnnals of the rheumatic diseases2008

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.

P Emery et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.